Axsome Therapeutics AXSM Payments for finance leases
Payments for finance leases at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's payments for finance leases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's payments for finance leases?
- Axsome Therapeutics (AXSM) reported payments for finance leases of $672K in Q1 2026.
- How has Axsome Therapeutics's payments for finance leases changed year-over-year?
- Axsome Therapeutics's payments for finance leases increased by 67.6% year-over-year, from $401K to $672K.
- What does payments for finance leases mean?
- Cash paid to reduce the principal balance of finance lease liabilities.
- How do you interpret payments for finance leases?
- Consistent payments indicate ongoing operational commitments to leased assets; sudden spikes may indicate lease buyouts or restructuring.
- How does payments for finance leases compare across companies?
- Standard for companies with significant physical infrastructure or equipment needs; comparable to debt service obligations.